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INTRODUCTION
P
eptide amphiphile (PA) molecules, consisting of a
hydrophilic peptide sequence covalently linked to a
hydrophobic moiety, self-assemble in highly ordered,
one dimensional cylindrical nanostructures.1–7 In these
supramolecular structures the hydrophobic moieties
remain in the nanostructure interior space by hydrophobic
collapse, while the hydrophilic peptide sequences are con-
sequently displayed on the nanostructure surface, with orien-
tation order resulting from -sheet formation during the
self-assembling process. In this sense, these nanostructures
differ from ordinary cylindrical micelles, which typically have
less ordered hydrophobic and hydrophilic compartments. The
peptide moiety, remaining on periphery of the nanostructure,
enables different chemical and biological functionalities. It has
been shown that this kind of nanostructures is able to template
the crystallographic orientation in hydroxyapatite minerali-
zation1 and to promote the selective differentiation of neural
progenitor cells.4 Moreover PA nanostructures functionalized
with bioactive sequences exhibit exceptional properties,
including the ability to reach in a selective way a biological
target,6 or allowing formation of pores in membranes.7
The self-assembly of PA into nanostructures creates a
dense hydrocarbon-like microenvironment within an aque-
ous gel. The environment created locally upon assembly
makes PA nanostructures and other self-assembling systems
potentially ideal candidates for the delivery of hydrophobic
or water-insoluble molecules in vivo.8 Amphiphilic struc-
tures, such as block copolymers, anionic, and cationic surfac-
tants, can sequester hydrophobic or lipid soluble organic
molecules in aqueous solution during or after the self-assem-
bly process.9 The presence of a bioactive exposed molecule
could be used for target-selective delivery of hydrophobic
no-water soluble drugs.10
We have investigated the assembling properties of a PA
molecule containing a dioctadecyl moiety as hydrophobic
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The self-assembling behavior, at physiological pH, of the
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pyrene, chosen as drug model, and the anticancer
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segment, a spacer consisting of a glycine residue and ﬁve
units of 8-amino-3,6-dioxaoctanoic acid, and the carboxyl
terminal sequence of the peptide hormone cholecystokinin,
CCK8, as bioactive hydrophilic peptide. The molecule was
designed considering that the hydrophobic dioctadecyl moi-
ety should favor formation of stable aggregates, while the
CCK8 peptide was selected for its potential use in biological
recognition. In fact, CCK8 displays high afﬁnity for both
CCK1 and CCK2 cholecystokinin receptors.
11 These receptors
have been often found overexpressed in several human
tumors12 and thus they represent potential targets for tumor
diagnosis and for drug delivery: the 111In radiolabel CCK8
analogue, [111In-DOTA]CCK8, bearing the chelating agent
tetraazacyclodecane tetraacetic acid (DOTA) at the N-termi-
nus of CCK8, is now in preclinical evaluation for scintigra-
phy of human medullary thyroid cancers overexpressing
CCK receptors;13 CCK8 functionalized macroaggregates have
signiﬁcant potential for selective delivery of drugs on a vari-
ety of cancerous tumors.
Here we described the synthesis of (C18)2L5CCK8 PA,
schematized in Figure 1, and its self-assembling behavior in
nanostructures at physiological pH. We also report on the
structural properties of the nanostructures as resulting by
Small-angle neutron scattering (SANS) studies and on the
conformation of the amphiphilic peptide on the external sur-
face of the aggregate as determined by CD spectroscopy.
Finally, ﬂuorescence experiments indicating the sequestration
of pyrene, chosen as drug model, and of Doxorubicin within
the nanostructures are reported. These studies provide help-
ful information to assess the use of this kind of supramolecu-
lar aggregates as potential carriers for selective delivery of
hydrophobic, poor water-soluble drugs.
EXPERIMENTAL METHODS
Materials and Methods
Protected N-Fmoc-amino acid derivatives, coupling reagents, and
Rink amide MBHA resin were purchased from Calbiochem-Nova-
biochem (Laufelﬁngen, Switzerland). The Fmoc-8-amino-3,6-diox-
aoctanoic acid (Fmoc-AdOO-OH) was purchased from Neosystem
(Strasbourg, France). The N,N-dioctadecylsuccinamic acid was syn-
thesized according to literature.14 All other chemicals were commer-
cially available by Sigma-Aldrich or Fluka (Buchs, Switzerland) or
LabScan (Stillorgan, Dublin, Ireland) and were used as received
unless otherwise stated. All solutions were prepared by weight with
doubly distilled water. The pH of all solutions was kept constant at
7.4 by using a 0.1M phosphate buffer solution.
Chemical Synthesis
Solid phase peptide synthesis was performed on a Shimadzu (Kyoto,
Japan) Model SPPS-8 fully automated peptide synthesizer. Analyti-
cal RP-HPLCs were carried out on a Shimadzu 10A-LC using a Phe-
nomenex C18 column (Torrance, CA), 4.6  250 mm, eluted with
H2O/0.1%TFA (A) and CH3CN/0.1%TFA (B) mixture. In the ana-
lytical method two gradients from 60 to 80% B over 10 min at
1.0 ml/min ﬂow rate and from 80 to 95% B over 15 min at 1.0 ml/
min ﬂow rate were used. Preparative RP-HPLCs were carried out on
a Waters (Milford, MA) model Delta Prep 4000 equipped with a UV
-Max Model 481 detector using a Vydac C18 column (Columbia,
MD), 22  250 mm, eluted with the H2O/0.1% TFA (A) and
CH3CN/0.1% TFA (B) mixture previously described and a linear
gradient at 20 ml/min ﬂow rate. Mass spectra were carried out on a
Maldi-tof Voyager-DE Perseptive Biosystem (Framingham, MA) ap-
paratus using the -cyano-4-hydroxycynnamic acid as matrix and
bovine insulin as internal reference.
(C18H37)2NCO(CH2)2CO(AdOO)5 G CCK8 [(C18)2L5CCK8].
The (C18)2L5CCK8 synthesis was carried out in solid-phase under
standard conditions using Fmoc strategy.15 Rink-amide MBHA
resin (0.78 mmol g, 1 mmol scale, 1.28 g) was used. The peptide
chain was elongated by sequential coupling and Fmoc deprotection
of the Fmoc-amino acid derivatives. All couplings were performed
twice for 1 h, by using an excess of 4 equivalents for the single
amino acid derivative. The -amino acids were activated in situ by
the standard HOBt/PyBop/DIPEA procedure. DMF was used as a
solvent. Fmoc deprotection was carried out by 20% solution of pi-
peridine in DMF after the coupling of each amino acidic residue.
When the Gly-CCK8 synthesis was complete, the Fmoc N-terminal
protecting group was removed and ﬁve residues of Fmoc-AdOO-
OH were added. They were condensed to the -NH2 of the glycine
residue in successive single couplings. An excess of two equivalents
of Fmoc-AdOO-OH, PyBop, and HOBt and four equivalents of
DIPEA were dissolved in DMF and added to the manual vessel.
When all ﬁve linkers were coupled on the peptide chain, the N,N-
dioctadecylsuccinamic acid, was bonded. The coupling was carried
out by an excess of four equivalents (2.48 g, 4.0 mmol) of the lipo-
philic compound dissolved in 10 ml of DMF/DCM (50/50) mixture.
2.080 g (4.0 mmol) of PyBop, 0.612 g (4.0 mmol) of HOBt and
1.34 ml (8.0 mmol) of DIPEA, dissolved in DMF were introduced in
the vessel like activating agents. The coupling time was 1 h under N2
ﬂow at room temperature. Yield for aliphatic acid coupling, moni-
tored by the Kaiser test, was in the range 95–98%. For deprotection
and cleavage, the fully protected resin was treated with a mixture of
triﬂuoroacetic acid (TFA), triisopropylsilane (TIS), ethanedithiol
FIGURE 1 Schematic representation of (C18H37)2NCO(CH2)2CO(AdOO)5 G CCK8 [(C18)2-
L5CCK8] peptide amphiphile.
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(EDT), and water in the TFA/TIS/EDT/H2O 93/2/2.5/2.5 ratio, and
the free product precipitated at 08C by adding water drop wise.
Puriﬁcation of the crude mixture was carried out by RP-HPLC (
¼ 280 nm), Rt ¼ 26.2 min. The ﬁnal product was recovered at pu-
rity higher than 95% and with a ﬁnal yield of 15%. Mass spectrum
conﬁrms the product identity (MW ¼ 2243, m/z ¼ 2244).
Preparation of the Solutions
Stock solutions of PA were prepared in 0.1M phosphate buffer at
pH 7.4, ﬁltered through a 0.45 m ﬁlter. Concentrations of all solu-
tions were determined by absorbance on a UV-vis Jasco (Easton,
MD) Model 440 spectrophotometer with a path length of 1 cm
using a molar absorptivity ("280) of 6845M
1 cm1 for CCK8. This
value was calculated according to the Edelhoch method,16 taking
into account contributions from tyrosine and tryptophan present in
the primary structure, which amount to 1215 and 5630M1 cm1,
respectively.17
Small-Angle Neutron Scattering
SANS measurements were performed at 258C at the FRJ-2 research
reactor in Ju¨lich (Germany), with the KWS2 spectrometer. Neutrons
with average wavelength of 6.3 A˚ and wavelength spread = < 0:1
were used. Neutrons scattered from the samples were detected by a
2D arrays detector at two different sample-detector distances, (2
and 8 m), to get scattering cross sections in a range of the scattering
vector modulus q, deﬁned as q ¼ 4= sinð=2Þ with  scattering
angle, comprised between 0.0053 and 0.16 A˚1. Samples, prepared
by weight using D2O as solvent, were contained in 1 mm path
length quartz cells, and measurement times ranged between 15 min
and 2 h. The data were then corrected for background, empty cell,
and solvent contributions and then reduced to absolute scattering
cross sections, by using a Plexiglas sample as standard.18
Atomic Force Microscopy
The AFM (Digital Instruments Nanoscope IIIa) was equipped with
a sharpened silicon tip with a radius less than 5 nm. Samples were
obtained dispersing the aggregates in acetone or ethanol diluted so-
lutions and depositing 20–30 l of such solutions on a mica sub-
strate. Images of the surface proﬁles were obtained by operating the
AFM in the tapping mode, with a scan size and rate of 3 m and
2 Hz, respectively.
Circular Dichroism Experiments
Far-UV CD spectra were collected at room temperature on a Jasco
Model J-715 spectropolarimeter using 1 mm path length quartz
cells. Other experimental settings were: scan speed, 10 nm/min; sen-
sitivity, 50 mdeg; time constant, 16 s; bandwidth, 3 nm. Circular
dichroism measurements were conducted on G-CCK8 and PA solu-
tions at concentrations of 1  104M in 2.5 mM phosphate buffer
at pH 7.4. The CD spectra were collected from 260 to 195 nm, cor-
rected for blank and adjusted for dilution.
Fluorescence Studies
Critical micellar concentration (cmc) values and an evaluation of
pyrene and Doxorubicin encapsulation were obtained by Fluores-
cence spectroscopy using 1 cm path length quartz cell. Emission
spectra were recorded at room temperature using a Jasco Model FP-
750 spectroﬂuorimeter. Equal excitation and emission bandwidths
were used throughout experiments, with a recording speed of
125 nm/min and automatic selection of the time constant. The cmc
of PA was measured by using 8-anilinonaphthalene-1-sulfonate
(ANS) as ﬂuorescent probe. Small aliquots of a self-assembled
aggregate solution (1  104M) were added to a ﬁxed volume of 1
 105M ANS dissolved in the same buffer. The cmc was deter-
mined by linear least-squares ﬁtting of the ﬂuorescence emission at
480 nm, upon excitation at 350 nm versus the amphiphile concen-
tration as previously reported.19,20 Pyrene and Doxorubicin encap-
sulation in PA were evaluated by titration experiments. The excita-
tion wavelength of pyrene and Doxorubicin were settled at 335 and
480 nm, respectively. Small amount of stock solutions of 2.0
 104M pyrene in ethanol in 2.5 mM phosphate buffer containing
0.9% wt NaCl, were added to 1.0  104M solution of PA or to
pure water. The repartition coefﬁcient between Doxorubicin in PA
solution/Doxorubicin in water was evaluated by a ﬂuorescence titra-
tion of PA in 8.6  107M of Doxorubicin solution.
RESULTS AND DISCUSSION
The self-assembling PA (C18)2L5CCK8 was synthesized by
solid-phase methods using Rink-amide MBHA resin as poly-
meric support and the Fmoc/tBu chemistry. The CCK8 pep-
tide was synthesized according to standard SPPS protocols.15
At the Asp N-terminal residue of the CCK8 peptide a glycine
residue and ﬁve units of 8-amino-3,6-dioxaoctanoic acid,
acting as spacers, were consecutively added. After the Fmoc
protecting group removal from the last ethoxylic spacer, the
N,N-dioctadecylsuccinamic acid was coupled on the free
NH2 terminus. The product, puriﬁed by preparative RP-
HPLC, was isolated in a 15% yield. Analytical data (Maldi-
tof mass spectrum and RP-HPLC) conﬁrm the compound
identity and its high purity. The self-assembling behavior of
(C18)2L5CCK8 was characterized by cmc measurements, CD
spectroscopy, and AFM images. The cmc value was deter-
mined by a ﬂuorescence-based method using ANS as probe.
The ﬂuorescence intensity at 480 nm, corresponding to the
maximum of spectrum, as a function of the PA concentration
is reported in Figure 2a. The break-point indicates a cmc
value of 2  106 mol kg1 that conﬁrms the high stability
of the resulting supramolecular aggregates.
In Figure 2b a comparison of the circular dichroism (CD)
spectra of the G-CCK8 nonapeptide and of the (C18)2L5CCK8
PA, above its cmc value, is reported. The G-CCK8 peptide
assumes a random-coil conformation as well expected for a
short peptide sequence.21 In contrast, PA shows a large nega-
tive maximum at 218 nm, corresponding to a -sheet struc-
tural motif due to the self-assembling of PA in nanostruc-
tures, driven by the interactions of the hydrophobic chains in
the inner core and by the peptide side chains in the hydro-
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philic shell.22 The presence of the peptide moiety in the
hydrophilic external shell is conﬁrmed by the presence of a
ﬂuorescence maximum at 360 nm that is diagnostic of the
hydrophilic environment of the indole group on tryptophan
side-chain (Figure 2c).23 Tryptophan exposition on the
hydrophilic shell of the aggregate suggests the bioavailability
of CCK8 peptide to the receptor binding site.
Figure 3 reports the absolute scattering cross sections
d=d obtained for the binary system (C18)2L5CCK8-D2O
(c ¼ 8.1  104 mol kg4). From the inspection of the SANS
pattern it is possible to highlight the presence of a two-scale
structure. The shoulder occurring in the region for which q
> 0.03 A˚1, can be ascribed to the scattering of relatively
small aggregates (micelles), i.e. formed by the aggregation of
(C18)2L5CCK8 molcules, that expose the hydrophilic moi-
eties toward the outer solvent, preserving the hydrophobic al-
kylic chains from the D2O. The increase of the cross section
at lower q (q < 0.03 A˚1) is caused by an upper level struc-
ture. In general, if we consider a fractal object with a fractal
dimension D, the scattering cross section scales with a power
law d=d / qD. In our case, the exponent D ¼ 3 observed
in Figure 3 indicates that in the region q < 0.03 A˚1 the
arrangement observed resemble a 3D structure.24 Since, no
Guinier regime is observed in the q range spanned by SANS
measurements, it is possible to conclude that linear dimen-
sions of this upper level structure is at least 2/qmin ¼ 100 nm.
Indeed, the AFM image of aggregates at high magniﬁcation,
reported in Figure 4a, revealed nanostructures with an aver-
age size of bright spots (966 20 nm).
The encapsulation of pyrene, a ﬂuorophoric compound
chosen as drug model, in the PA nanostructure was investi-
gated in phosphate buffer solution. Pyrene presents a very
low water solubility (2.5  105M), but its solubility strongly
increases in nanostructure containing water solutions
because of its entrapment in the hydrophobic core of the
nanostructure obtained by PA aggregation.8 The entrapment
process has been studied by comparing the ﬂuorescence spec-
FIGURE 2 (a) Fluorescence intensity of ANS ﬂuorophore at
480 nm versus PA concentration. Cmc value (2  106 mol kg1) is
established from graphical break-point; (b) CD spectra of 1.0
 104M G-CCK8 nonapeptide (—) and 1.0  104M
(C18)2L5CCK8 peptide amphiphile (—) in 0.1M phosphate buffer
at pH 7.4; (c) Fluorescence spectrum of tryptophan residue in 1.0
 104M (C18)2L5CCK8 peptide amphiphile. The spectrum was
excited at 280 nm.
FIGURE 3 Scattering cross sections obtained at 258C for a
solution 8.1  104 mol kg1 of the (C18)2L5CCK8 peptide
amphiphile.
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tra of pyrene in water solution and in 1.0  104M PA con-
taining solution, both buffered at pH 7.4. In both solutions
increasing amounts of pyrene (from 6.0  107 to 1.8
 105M) were added, following the titration by recording
ﬂuorescence spectra (titrations are reported in Figure 5). The
ﬂuorescence emission spectrum of pyrene shows vibrational
bands that are affected by the polarity of the surrounding
environment of the probe molecules. Speciﬁcally, changes in
the relative intensity of the ﬁrst (I1 at 373 nm) and the third
(I3 at 393 nm) vibrational bands in the pyrene emission spec-
trum have been proven to be reliable tools in examining the
polarity of the microenvironment.25 Moreover, the ﬂuores-
cence emission at 480 nm is diagnostic for excimer formation
within the nanostructures.8 Both the relative intensity varia-
tion of the bands at 373 and 393 nm (I1/I3 changes from 1.11
to 0.85) observed by comparing the titration in absence and
in presence of PA, as well the appearing of the 480 nm band
by adding pyrene to PA containing water solution, indicate
the entrapment of pyrene in the inner hydrophobic region of
the PA nanostructures.
To rule out the occurrence of several interactions of py-
rene molecule with the ethoxylic spacers interposed between
hydrophobic chains and the bioactive CCK8 peptide in PA
molecule, additional ﬂuorescence control experiments were
carried out. We found that ﬂuorescence titration of pyrene in
1.0  104M solution of PEG-600 (chosen for its similar
length to ﬁve ethoxylic AdOO linkers) is comparable with
pyrene titration in water solution. Moreover, similar experi-
ments were also carried out by using a 1.0  104M of CCK8
or amphiphilic compound at concentration below its cmc, in
water solution, to exclude pyrene interaction with the octa-
peptide fragment and with PA in non aggregated form,
respectively. The results indicate that the variation of ﬂuores-
cence emission spectra of pyrene could be only attributed to
the incorporation of the ﬂuorophore in already formed PA
nanostructures.
We have also investigated the efﬁciency of PA nanostruc-
tures in loading anticancer molecules, such as the cytotoxic
drug Doxorubicin, in their inner compartment. Fluorescence
FIGURE 4 (a) AFM image of PA aggregates at 1  105 mol kg1; (b) Diameter histogram distri-
bution for aggregates.
FIGURE 5 (a) Fluorescence titration of pyrene in water solution
and in (b) 1.0  104M peptide amphiphile containing solution,
both buffered at pH 7.4. Different amounts of pyrene, from 6.0
 107 to 1.8  105M, as ﬁnal concentration, are added.
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titration of PA was carried out on a 8.6  107M Doxorubi-
cin containing solution, buffered at pH 7.4. As already
reported,26 the ﬂuorescence intensity of Doxorubicin, as well
as the other molecules belonging to the anthracycline family,
increases when it is encapsulated in nanostructure: in fact the
hydrophobic environment avoids the dynamic quenching
because of collisions with water molecules.
Fluorescence measurements allowed extracting the value
of the partition constant Kr deﬁned according to Eq. (1)
Kr ¼
½DðPAÞ
½DðwÞ
ð1Þ
where [D](PA) and [D](w) are the concentration of Doxorubi-
cin in the inner compartment of PA aggregates and in the
external water, respectively. To evaluate Kr , a titration of a 8.6
 107M Doxorubicin solution with increasing amounts of
PA has been performed. Fluorescence intensity at 590 nm has
been recorded as a function of PA concentration I590(cPA).
Fluorescence intensity I590 for a solution of Doxorubicin in
water at the same concentration used for the titration (8.6
 107M) has also been measured. From these values it is
possible to evaluate the molar fraction of Doxorubicin
xD(cPA) dissolved in the hydrophobic environment, according
to Eq. (2)
xDðcPAÞ ¼
nðPAÞ
nðPAÞ þ nðwÞ
ð2Þ
where n(i) represents the moles of Doxorubicin dissolved in
the phase i. xD(cPA) is correlated to the ﬂuorescence inten-
sities through the relation
xDðcPAÞ ¼ I590ðcPAÞ  I590
I1590  I590
ð3Þ
where I1590 is the limit ﬂuorescence intensity of Doxorubicin,
obtainable through an extrapolation of ﬂuorescence inten-
sities I590(cPA). Algebraic manipulations allow correlating Kr
with xD(cPA)
1
xDðcPAÞ ¼ 1þ
1
Kr
1
ðcPAÞ  1
 
ð4Þ
where  is the fraction volume of the hydrophobic aggregates.
The volume fraction  is obtained from the stoichiometric
concentration C of the PA molecules. Volume fraction  is
deﬁned as the ratio between the volume of all the PA aggre-
gates VPA and the volume of the system V
 ¼ VPA
V
ð5Þ
Volume VPA can be written as the product of the molecular
volume vPA of PA (estimated in *3000 A˚
3) and the number
of PA molecules present in the system as micelles NPA
 ¼ vPANPA
V
ð6Þ
But the ratio NPA/V can be identiﬁed as the concentration of
PA monomers present in the micelles cPA
 ¼ vPANPA
V
¼ vPALAcPA ð7Þ
In turn cPA can be written as the difference between the stoi-
chiometric PA concentration C and the critical micellar con-
centration cmc
 ¼ vPANPA
V
¼ vPALAcPA ¼ vPALAðC  cmcÞ ð8Þ
from which the volume fraction  is readily calculated. Thus,
by plotting 1/xD vs. 1/  1 the partition constant, as the re-
ciprocal of the angular coefﬁcient of the ﬁt line, is obtained.
Figure 6 reports the reciprocal of the molar fraction of
Doxorubicin dissolved in the hydrophobic environment vs.
1/  1, along with the line that has been ﬁt to the experi-
mental data. From the ﬁtting procedure it has been obtained
for Kr the value (5.0 6 0.5)  105, that indicates a strong
preference of Doxorubicin for the inner hydrophobic envi-
ronment of PA structures.
FIGURE 6 Reciprocal of the molar fraction xD of Doxorubicin
dissolved in the hydrophobic environment of PA aggregates vs.
1= 1, along with the line ﬁt to the experimental data.
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CONCLUSIONS
(C18)2L5CCK8 PA is able to self-assemble spontaneously in
well-ordered nanostructures in aqueous solution. These
nanostructures, fully characterized by structural measure-
ments, are able to encapsulate poorly water soluble molecules
such as pyrene and Doxorubicin in their hydrophobic com-
partment. The encapsulation process can be followed and
quantiﬁed by ﬂuorescence technique. The reported PA supra-
molecular aggregates could be employed for target selective
drug delivery of hydrophobic drugs on a biological target,
through the bioactive peptide exposed on the external sur-
face. In fact, the bioactive CCK8 peptide exposed on the
external surface of the nanostructures could interact with
cholecystokinin receptors overexpressed by cancer cells. In
this way the entrapped drug is mainly delivered in proximity
of the tumor, thus reducing the well-expected toxic side
effects on non-target organs.
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